Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC alone versus ASC plus FOLFOX in previously treated advanced biliary tract cancer
2013-001812-30Phase 3Completed
- Sponsor
- The Christie
- Start
- Sep 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, folinic acid and fluorouracil in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer and 1 more (2 arms), sponsored by The Christie. Primary endpoint: Overall survival. Started Sep 2013; status: completed.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on 2013-001812-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001812-30.